The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells
Open accessAbstract
Peroxisome proliferator-activated receptor-γ (PPARγ), a member of the nuclear hormone receptor superfamily originally shown to play an important role in adipocyte differentiation and glucose homeostasis, is now known to regulate inflammatory responses. Given the importance of endothelial cell (EC)-derived chemokines in regulating leukocyte function and trafficking, we studied the effects of PPARγ ligands on the expression of chemokines induced in ECs by the Th1 cytokine IFN-γ. Treatment of ECs with PPARγ activators significantly inhibited IFN-γ-induced mRNA and protein expression of the CXC chemokines IFN-inducible protein of 10 kDa (IP-10), monokine induced by IFN-γ (Mig), and IFN-inducible T-cell α-chemoattractant (I-TAC), whereas expression of the CC chemokine monocyte chemoattractant protein-1 was not altered. PPARγ activators decreased IFN-inducible protein of 10 kDa promoter activity and inhibited protein binding to the two NF-κB sites but not to the IFN-stimulated response element ISRE site. Furthermore, PPARγ ligands inhibited the release of chemotactic activity for CXC chemokine receptor 3 (CXCR3)-transfected lymphocytes from IFN-γ-stimulated ECs. These data suggest that anti-diabetic PPARγ activators might attenuate the recruitment of activated T cells at sites of Th1-mediated inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630
Self-citationLehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Loetscher, M., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.963 · Cited by 1,193
Cited by
Current Concepts of the Pathogenesis of the Acute Coronary Syndromes
Libby, P. (2001) · Circulation · doi:10.1161/01.cir.104.3.365 · Cited by 1,558
Self-citationImmune Mechanisms in Atherosclerosis
Hansson, G. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100220 · Cited by 876
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.013 · Cited by 820
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases
Antonelli, A., Ferrari, S. M., Giuggioli, D., Ferrannini, E., Ferri, C., & Fallahi, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.010 · Cited by 595
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
High Glucose-Induced Expression of Proinflammatory Cytokine and Chemokine Genes in Monocytic Cells
Shanmugam, N., Reddy, M. A., Guha, M., & Natarajan, R. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1256 · Cited by 526
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
BEAL, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 523
Immune mechanisms in atherosclerosis.
Hansson, G. K., Jonasson, L., Seifert, P. S., & Stemme, S. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.5.567 · Cited by 515
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Self-citationPPARγ as a new therapeutic target in inflammatory bowel diseases
Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P., Chamaillard, M., & Desreumaux, P. (2006) · Gut · doi:10.1136/gut.2006.093484 · Cited by 450
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Fatty Acid Regulation of Gene Transcription
Jump, D. B. (2004) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360490278341 · Cited by 356
15d-PGJ2: The anti-inflammatory prostaglandin?
Scher, J. U., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.008 · Cited by 348
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Self-citationThe role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Role of CXCL1 in tumorigenesis of melanoma
Dhawan, P., & Richmond, A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.9 · Cited by 303
Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294
Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett-Racke, A. E., Drew, P. D., & Racke, M. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2508 · Cited by 291
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
Watanabe, T., Asano, N., Fichtner-Feigl, S., Gorelick, P. L., Tsuji, Y., Matsumoto, Y., Chiba, T., Fuss, I. J., Kitani, A., & Strober, W. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39481 · Cited by 262
The Anti-Inflammatory Effects of Prostaglandins
Scher, J. U., & Pillinger, M. H. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31819aaa76 · Cited by 259
Role of Chemokines in Endocrine Autoimmune Diseases
Rotondi, M., Chiovato, L., Romagnani, S., Serio, M., & Romagnani, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0044 · Cited by 257
Shiomi, T., Tsutsui, H., Hayashidani, S., Suematsu, N., Ikeuchi, M., Wen, J., Ishibashi, M., Kubota, T., Egashira, K., & Takeshita, A. (2002) · Circulation · doi:10.1161/01.cir.0000039346.31538.2c · Cited by 255
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke, F., Takata, Y., Caglayan, E., Law, R. E., & Hsueh, W. A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191663.12164.77 · Cited by 176
Montes de Oca, P., Macotela, Y., Nava, G., López-Barrera, F., de la Escalera, G. M., & Clapp, C. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700256 · Cited by 71
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
Endothelium as a gatekeeper of fatty acid transport
Mehrotra, D., Wu, J., Papangeli, I., & Chun, H. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.11.001 · Cited by 60
Ferrari, S. M., Ragusa, F., Paparo, S. R., Nasini, F., Nardi, M., Franceschini, S. S., Fallahi, P., & Antonelli, A. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.05.004 · Cited by 26
Metadata
- Authors
- Marx, N., Mach, F., Sauty, A., Leung, J. H., Sarafi, M. N., Ransohoff, R. M., Libby, P., Plutzky, J., & Luster, A. D.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-06
- Volume
- 164
- Issue
- 12
- Pages
- 6503-6508
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2150652688
- Cited by
- 296
- References
- 32
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.